Abstract
Objective It has been asserted that high-frequency analysis of intracranial EEG (iEEG) data may yield information useful in localizing epileptogenic foci.
Methods We tested whether proposed biomarkers could predict lateralization based on iEEG data collected prior to corpus callostomy (CC) in patients with bisynchronous epilepsy, whose seizures lateralized definitively post-CC. Lateralization data derived from algorithmically-computed ictal phase-locked high gamma (PLHG), high gamma amplitude (HGA) and line length (LL), as well as interictal high-frequency oscillation (HFO) and interictal epileptiform discharge (IED) rate metrics were compared against ground-truth lateralization from post-CC ictal iEEG.
Results Pre-CC unilateral IEDs were more frequent on the more-pathologic side in all subjects. HFO rate predicted lateralization in one subject, but was sensitive to detection threshold. On pre-CC data, no ictal metric showed better predictive power than any other. All post-corpus callosotomy seizures lateralized to the pathological hemisphere using PLHG, HGA and LL metrics.
Conclusions While quantitative metrics of IED rate and ictal HGA, PHLG and LL all accurately lateralize based on post-CC iEEG, only IED rate consistently does so based on pre-CC data.
Significance Quantitative analysis of IEDs may be useful in localizing seizure pathology. More work is needed to develop reliable techniques for high-frequency iEEG analysis.
Highlights
We evaluated intracranial EEG biomarkers in corpus callostomy patients with bisynchronous seizures pre-operatively.
Despite testing more contemporary metrics, only interictal epileptiform discharge counting consistently lateralized seizure foci.
High-frequency metrics, especially high-frequency oscillation counting, appear to be sensitive to parameter selection.
Competing Interest Statement
A.D.M. has consulting agreements with Medtronic and P.M.T. Corporation.
Funding Statement
A.D.M. receives funding from the following grants: NIH/NINDS NS098976-01, NSF-BSF-2017015; NIMH MH114166-01; S.K. is supported by the Feinstein M.D. Scholarship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were approved by the Institutional Review Board of the Feinstein Institutes for Medical Research, Northwell Health.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.